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HEALTH ECONOMIC OUTCOME ANALYSIS OF STEM CELL MOBILIZATION
WITH GRANULOCYTE COLONY-STIMULATING FACTOR (G-CSF) PLUS
PLERIXAFOR VERSUS G-CSF ALONE IN PREPARATION FOR AUTOLOGOUS
STEM CELL TRANSPLANTATION (ASCT) IN PATIENTS WITH NON-HODG-
KIN’S LYMPHOMAS (NHL)
Pusic, I.1, Kymes, S.M.2, Lambert, D.L.2, Gregory, M.2, DiPersio, J.F.1
1Washington University School of Medicine, Siteman Cancer Center, St.
Louis, MO; 2Washington University School of Medicine, Ophthalmology
and Visual Sciences, St. Louis, MO
Background: Most commonly used mobilization methods for
ASCT include G-CSF, however no standard approach has been es-
tablished. Plerixafor (Mozobil), a competitive inhibitor of
CXCR4, when given with G-CSF mobilizes more CD34 cells/
apheresis resulting in a higher total CD34 cells/kg yield. We con-
sider the cost-benefit of G-CSF plus plerixafor (G + P) vs G-CSF
alone (G) for stem cell mobilization in NHL patients undergoing
ASCT.
Methods: We constructed a decision analytic model comparing
G + P to G in patients with NHL. The probabilities in the model
were taken from a recent randomized trial at Washington Univer-
sity (n5 41) comparing these two mobilization regimens. In the
trial, patients received G + P or G+placebo for initial mobilization.
In both arms, if minimal goal of 2  106 CD34 cells/kg was not
achieved after 4 aphereses, remobilization was conducted with
G + P. The model estimated costs for mobilization and remobiliza-
tion, but didn’t consider the transplant. The payor perspective was
taken with allowed charges, including medication, estimated using
Medicare allowable.
Results: In the G + P arm all patients (21/21) achieved the minimal
goal of CD34 cells after initial mobilization and proceeded to ASCT,
while in the G arm only 12/20 proceeded to ASCT. Of 8/20 remain-
ing G-patients, 2 were never remobilized, 6 were remobilized, but of
these only 4/6 achieved the minimal CD34 cell count required and
proceeded to ASCT. Adjusting for the lower enrollment in the G
arm, total allowed charges for mobilization of patients in the G + P
arm was $109,480 more than patients in the G arm. Had additional
mobilization been attempted for those patients in the G arm who
failed mobilization or remobilization (n5 4), the costs in the G
arm would have increased by $69,512, reducing the difference be-
tween groups to $39,968. We didn’t consider treatment or social
costs associated with the decision not to transplant following a failed
mobilization, as the events associated with these care processes were
not tracked in the trial. Conclusions: Taking a cost-benefit approach
we found that the G + P regimen in this trial cost $1,998 per patient
more than the G. This additional cost resulted in a 20% greater
probability of transplant in theG + P arm. Given the small difference
in cost, and large potential benefit, it is expected that future analyses
considering the social benefit of successful transplant will show that
the G + P regimen easily meets most accepted standards of cost-ef-
fectiveness.
G1 Placebo G1 PProbability of transplant 80.0% (16/20) 100% (21/21)
Probability of
remobilization30.0% ( 6/20) N/ATotal cost per patient (SD) $ 12,458 (13,193) $ 17,932 (8,206)
Incremental cost per
patient$ 5,474Estimated cost per
remobilization*$ 17,376Incremental cost after
adjustment for failed
mobilization$ 1,998*Remobilization protocol included plerixfor146
HEMATOPOIETIC STEM CELL APHERESIS PRODUCTS WITH HIGH MID-
COLLECTIONWBC COUNTS ARE AN ACCURATE INDICATOROF THE FINAL
PRODUCT WBC COUNT AND ARE ASSOCIATED WITH TRANSPLANT RE-
LATED ADVERSE EVENTS
Islas-Ohlmayer, M.1, Potter, G.W.2, Shaughnessy, P.2, LeMaistre, C.F.2,
Huerta, J.2, Folkert, J.2, Bachier, C.2 1University of Texas Health Science
Center at San Anonio, TX; 2Texas Transplant Institute, San Antonio, TX
We randomly reviewed 159 patients (pts) at our institution who
underwent hematopoietic stem cell (HSC) collection with either
a COBE spectra cell separator (CS) (n5 85) or Fresenius AS 104
cell separator (F) (n5 74). Products collected using the CS had
higher total WBC count when compared to the F (163 +/- 136 K/
uL vs. 55 +/- 29 K/uL, p\0.001) but a lower percentage of mono-
nuclear cells (MNC) (75% +/- 23% vs. 85% +/- 11%, p\0.001).
Unexpected transplant related adverse events were seen in 3 pts
who experienced tonic-clonic seizures and 1 pt with delayed engraft-
ment. These pts all received HSC apheresis products with WBC
counts over 590 K/uL, which was significantly higher than the me-
dian WBC counts on all apheresis products, and all were collected
using CS. No apheresis products were diluted prior to cryopreserva-
tion or infusion.
We subsequently reviewed 21 consecutive HSC apheresis prod-
ucts from 13 separate pts and analyzed WBC, MNC, and CD34
cell counts at 3 different time points, pre, mid and post-collec-
tion. Apheresis products with WBC counts greater than 400 K/
uL were diluted with normal saline (NS) prior to cryopreserva-
tion. Pts’ diagnoses were comprised only of hematological malig-
nancies, and included both auto (n5 19) and allogeneic (n5 2)
HSC collections. Products were collected using the CS (n5 10)
and the F (n5 11). Two pts had post collection WBC counts
over 400 K/uL and both were collected using the CS. Both prod-
ucts were diluted with NS prior to cryopreservation. One of the
two products was associated with delayed engraftment and 84%
donor chimerism at day 100. No other transplant related adverse
events were identified.
Analysis of the pre, mid, and post cell counts on theHSC apheresis
products revealed mid WBC values that accurately predicted post
apheresis product WBC counts (Table). The ease and rapidity of
mid apheresis WBC count analysis may allow the apheresis proce-
dure to be modified if WBC counts greater than 400 K/ul are pre-
dicted. We plan to prospectively assess mid WBC counts on all
apheresis procedures that use CS. Products with mid
WBC. 400 K/uL will get additional plasma collected so the final
product can be diluted with autologous plasma. Accurate and timely
identification of high risk apheresis products can obviate the unnec-
essary dilution of all products and therefore help decrease the cost
associated with cryopreservation of apheresed HSC products.
WBC, MNC and CD 34 Cell Counts Mid and Post Apheresis
WBC (k/uL) MNC (%) CD34x106/kgCOBE MID POST MID POST MID POSTMEAN 1/- SD 273 1/- 230 281 1/- 186 76 1/- 22 86 1/- 16 3 1/- 4 6 1/- 8RANGE 819 596 75 53 9 23FRESENIUS MID POST MID POST MID POSTMEAN 1/- SD 71 1/- 22 75 1/- 20 88 1/- 5 90 1/- 5 1 1/- 0.8 2 1/- 1RANGE 69 67 20 16 2 4Mid - cell counts mid way through a 10-12 L collection, Post -cell counts
at the end of a 20-24 L collection147
RELATIVE EFFICIENCY OF CORD BLOOD RBC DEPLETION BY SEPAX ELU-
TRIATION AND MANUAL REDUCTION
Miller, C.N., Miller, S.N., Flannery, S., Stockinger, S., Gutman, J.,
Quinones, R., Freed, B.M. University of Colorado Denver ClinImmune
Labs, Aurora, CO
Infusion of cord blood units with high RBC volume has been re-
ported to increase the health risk for recipients. Therefore the
Poster Session I S213most effective cord blood processing method results in the highest
total nucleated cell (TNC) count recovery with RBC volume of
\20 ml. In order to determine the most efficient automated and
manual processes, we compared units RBC-depleted by elutriation
(Sepax) with units that were RBC-depleted manually. Sepax process-
ing was performed with final processing volumes of 45 ml
(n5 1001), 35 ml (n5 18) or 25 ml (n5 9); manual processing was
performed by removing the equivalent of 0-40% of the starting vol-
ume from the RBC pellet (40% n5 17; 30% n5 9); 20% n5 14;
10% n5 6 and 0% n5 18). The TNC recoveries of units processed
by Sepax were equivalent at 45 ml (88%), 35 ml (87%), and 25 ml
(88%). Units processed with manual RBC depletion resulted in de-
creased TNC recoveries with greater RBC depletion (90% recovery
at 0% reduction vs. 81% TNC recovery at 40% reduction). The
mean final RBC volumes were significantly lower in the units pro-
cessed by Sepax (5.9 ml at 25 ml; 9.5 ml at 35 ml; 14.6 ml at 45 ml)
compared to the units that were manually RBC-depleted (17 ml at
40% reduction vs. 27 ml at 0% reduction). We conclude that RBC
depletion to \20 ml can be routinely achieved with any Sepax
method or by manual depletion of 40% of the starting volume
from the RBC pellet.HEMATOPOIESIS/MESENCHYMAL CELLS
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THE USE OF F-18 THYMIDINE IMAGING FOR EVALUATION OF THE BONE
MARROW COMPARTMENT FOLLOWING TRANSPLANTATION
Holter, J.L.1, Awasthi, V.2, Thorp, K.K.1, Anderson, S.4, Chacko, G.N.3,
Epstein, R.1 1University of Oklahoma, Oklahoma City, OK; 2University
of Oklahoma, Oklahoma City, OK; 3Oklahoma Pet Center, Oklahoma
City, OK; 4University of Oklahoma, Oklahoma City, OK
Evaluation of engraftment following bonemarrow transplantation
is based on measurements of marrow growth including peripheral
blood counts and bone marrow biopsies done weeks following trans-
plant. Early prediction of marrow function becomes increasingly
necessary as cord blood use increases, in evaluation of intentional
or unintentional radiation exposure, for evaluation of minimal resid-
ual disease, and to maximize treatment efficacy in hematologic ma-
lignancies. F-18 Flourothymidine (FLT)/PET imaging is being
evaluated clinically for tumor detection and staging. Unlike the
more commonly used FDG/PET, FLT is tied to proliferative activ-
ity and cellular growth by thymidine’s inclusion into DNA, and is
therefore less hampered by inflammatory background. We describe
the use of FLT in two groups, 1) a rat model of ablative and non-
myeloablative transplantation, and 2) normal and lymphoma patients
undergoing treatment.
In our rat model, we evaluated if imaging could provide early
evidence of hematopoietic recovery following radiation and trans-
plantation. Rats received myeloablative, non-myeloablative, and
sham transplantation with imaging at baseline, 24-48 hours after
transplantation and 6 days post-transplantation. As seen in Table
1, analysis confirms that FLT predicts engraftment as early as
24-48 hours following transplantation, FLT also can predict
lack of engraftment and radiation effect in sham transplantations
who did not receive stem cell infusion. Figure 1 illustrates FLT
and FDG imaging performed in a normal, post radiation and
post transplant rat, confirming superiority of FLT in evaluating
marrow function.
In our humanmodel, we evaluated if imaging could be used to pro-
vide useful information about chemotherapeutic and radiation ef-
fects on marrow. We imaged 6 patients with intracranial
malignancy with normal bone marrow as controls. In addition, we
imaged 3 lymphoma patients prior to treatment, at day 9 post-che-
motherapy, and following six cycles of chemotherapy. Figure 2 illus-
trates differences seen in FLT in a patient with normal marrow and
a patient with known marrow involvement. Our human and animal
model confirm that FLT can be used as a marker of cellular prolifer-
ation in the bone marrow. We propose that this tool could be used
for early evaluation of engraftment, success of chemotherapy,
prediction of radiation injury, and evaluation of minimal residual









rat studiesn5 10 n5 6 Normal cellular
marrow24-48 hrs post
950 cGy TBIn5 6 n5 4 Marrow damage
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TBIn5 4 not performed Aplastic marrowDay 6-7 post
950 cGy TBI
(4-5 days post





transplantationn5 4 n5 2 Cellular marrowDay 6-7 post
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SUICIDE CASPASE 9 GENE FOR IMPROVED SAFETY OF THERAPIES USING
MESENCHYMAL STROMAL CELLS
Ramos, C.A., Asgari, Z., Yvon, E., Heslop, H.E., Rooney, C.M.,
Brenner, M.K., Dotti, G. Baylor College of Medicine, Houston, TX
AlthoughMSC have been administered to hundreds of patients so
far withminimal reported side effects, little is known about their long
term effects. Recent reports of osteosarcoma formation in culture
and interference with major organ function due to ectopic ossifica-
tion raise safety concerns. In light of these, we sought to develop
a system allowing control over the growth and survival of MSCs ad-
ministered therapeutically, using an inducible caspase-9 (iCasp9)
protein that can be activated by a specific chemical inducer of dimer-
ization (CID) leading to cell death.
MSCs from healthy donors were retrovirally transduced with
iCasp9 linked to a truncated form of CD19, allowing selection
of transduced cells: 476 6% of the cells were iCasp9+, a percent-
age stable over more than two weeks in culture, suggesting no
deleterious or growth advantageous effects of the construct on
MSCs. iCasp9+ cells were easily immunomagnetically selected.
Phenotype (.99% CD73+CD90+CD105+, and negative for he-
matopoietic markers) and differential potential of iCasp9+ cells
was identical to that of untransduced cells, proving the genetic
manipulation of MSCs did not modify their basic characteristics.
Non-transduced MSCs had a spontaneous rate of apoptosis in
culture 18% (67%), similar to iCasp9+ cells at baseline
(156 6%, P5 0.47). Addition of CID to cultures after transduc-
tion resulted in apoptotic death of .90% of iCasp9+ cells
(936 1%, P\0.0001), while iCasp9– cells retained an apoptosis
index similar to that of non-transduced controls (206 7%,
P5 0.99 and P5 0.69 vs. non-transduced controls with or with-
out CID respectively), demonstrating that iCasp9+ MSCs can be
selectively killed. Addition of CID to cultures of differentiated
MSCs resulted in widespread apopotosis as assessed by TUNEL
assay. Furthermore, using an in vivo imaging system, we saw that
iCasp9+ MSCs injected subcutaneously in SCID mice were selec-
tively eliminated after administration of CID, without toxic ef-
fects.
In summary, MSCs are easily transduced with our iCasp9 sys-
tem, the transduced cells can be selected with clinical grade pro-
cedures and maintain their basic physiology, and their
differentiated progeny can be selectively eliminated by exposure
to a CID, analogues of which have been safely tested in a phase
I study. This directed MSC killing provides a necessary safety
mechanism for therapies using progenitor cells. This approach
will become of increasing value as clinical applications for MSCs
develop further.
